Drug news
Arcalyst (Regeneron) is filed at FDA for Gout Flares
The FDA has accepted the supplemental Biologics License Application for Arcalyst (rilonacept) injection from Renereron, for subcutaneous use for the prevention of Gout Flares in patients initiating uric acid-lowering therapy. The FDA plans to review the application on July 30 2012. Arcalyst is already available in the USA and EU for treatmentof rare genetic cryopyrin-associated periodic syndromes (CAPS).
Arcalyst is already sold for cryopyrin-associated periodic syndromes (CAPS), a rare genetic autoinflammatory disease
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.